82 related articles for article (PubMed ID: 20615173)
1. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
2. New dosing schedules of dasatinib for CML and adverse event management.
Wong SF
J Hematol Oncol; 2009 Feb; 2():10. PubMed ID: 19236716
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.
Haslam S
Core Evid; 2005; 1(1):1-12. PubMed ID: 22496672
[TBL] [Abstract][Full Text] [Related]
4. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Experts in Chronic Myeloid Leukemia
Blood; 2013 May; 121(22):4439-42. PubMed ID: 23620577
[TBL] [Abstract][Full Text] [Related]
5. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy.
Bonifacio M; Maheshwari V; Tran D; Agostoni G; Filioussi K; Viana R
Pharmacoecon Open; 2022 Jan; 6(1):95-104. PubMed ID: 34297312
[TBL] [Abstract][Full Text] [Related]
6. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
Bower H; Björkholm M; Dickman PW; Höglund M; Lambert PC; Andersson TM
J Clin Oncol; 2016 Aug; 34(24):2851-7. PubMed ID: 27325849
[TBL] [Abstract][Full Text] [Related]
7. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.
Smith AG; Painter D; Howell DA; Evans P; Smith G; Patmore R; Jack A; Roman E
BMJ Open; 2014 Jan; 4(1):e004266. PubMed ID: 24435897
[TBL] [Abstract][Full Text] [Related]
8. The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia.
Zhu Y; Pan L; Hong M; Liu W; Qiao C; Li J; Qian S
J Biomed Res; 2014 Sep; 30():. PubMed ID: 27346465
[TBL] [Abstract][Full Text] [Related]
9. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.
Saret CJ; Winn AN; Shah G; Parsons SK; Lin PJ; Cohen JT; Neumann PJ
Blood; 2015 Mar; 125(12):1866-9. PubMed ID: 25655601
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature.
Alharbi B; Alamri S; Mahdi A; Marghalani S
Case Rep Dermatol Med; 2018; 2018():4062431. PubMed ID: 30112222
[TBL] [Abstract][Full Text] [Related]
11. Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients.
Saverno KR; Rochau U; Stenehjem DD; Morley K; Siebert U; Brixner DI
J Manag Care Pharm; 2012; 18(6):457-63. PubMed ID: 22839687
[No Abstract] [Full Text] [Related]
12. Treatment of Cancer Gene Changes in Chronic Myeloid Leukemia by Big Data Analysis Platform-Based Dasatinib.
Song L; Li Q; Shi H; Zhang P
Appl Bionics Biomech; 2022; 2022():9294634. PubMed ID: 35721237
[TBL] [Abstract][Full Text] [Related]
13. Reduced-dose dasatinib in chronic-phase CML.
Das M
Lancet Oncol; 2018 May; ():. PubMed ID: 29759812
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
